This text relies on TheStreet’s Inventory & Markets Podcast. Hosted by Chris Versace, the veteran Wall Avenue investor and lead portfolio supervisor for TheStreet Professional, the weekly podcasts can be found early to members of TheStreetPro investing membership.
The important thing phrase right here is “humane.”
Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech firm, confused that time with TheStreet Professional’s Chris Versace through the Dec. 3 version of the Shares & Markets Podcast.
Versace defined that the biopharmaceutical drug most cancers market is predicted develop from roughly $225 million in 2024 to considerably increased figures over the following decade.
Some sources consider this market may exceed $360 billion by 2030–2034, pushed by rising most cancers charges, superior therapies, and, Versace added, “a strategy that is near and dear to our heart of the Pro portfolio, the aging population.”
“We want to find a more humane cure for cancer,” Breen stated, “because at the moment, if anyone is unfortunate enough to get cancer, the solutions that you’re given have been around since just after the Second World War.”
Breen analyzed the choices presently dealing with most cancers sufferers.
GT Biopharma will likely be making use of for an investigational new drug utility with the FDA.
Picture by Anadolu on Getty Photographs
CEO: Remedy far more humane
“The first one is obviously surgery,” he stated, “where they take a scalpel to you to cut out the cancer. But of course, the cancer, because it’s moving around your blood system, could have spread.”
The second, Breen added, “is they’re going to poison your blood with chemotherapy.”
Extra on well being care:
- Dave Ramsey sounds nationwide Medicare alarm
- Medicare drug choice can have main influence on older girls
- What Medicare Half B value hike means on your 2026 Social Safety
- FDA restricts kids’s well being merchandise over security considerations
- What doom scrolling does to your psychological well being
“You’re going to feel incredibly sick, which also, ironically, I think a lot of people don’t actually realize this,” he stated. “The chemotherapy kills your natural killer cells.”
“After you’re given chemotherapy, they tell you not to go out and not to mix with anyone who might be ill because your immune system has been wiped out.”
And the third possibility is radiotherapy, which, Breen stated, “is burning your flesh.”
“Our molecule is a protein,” he defined. “It can be given by intravenous infusion or, in relation to the solid tumor trial, which we’re hoping to start next year, it’ll be from subcutaneous injection. So, it’s so much more humane.”
Based on GT Biopharma’s Michael Breen, the corporate’s new most cancers remedy drug is extra humane than conventional interventions.
GT Biopharma
Breen stated GT Biopharma will likely be submitting an investigational new drug utility with the U.S. Meals & Drug Administration both by the tip of the 12 months or within the early a part of January, “and we’re hoping that that trial will start in the first half of 2026.”
“And we are going to target all of the main, most prolific solid tumors,” he stated. “I’m talking about bladder cancer, pancreatic cancer, ovarian cancer, lung cancer, head and neck cancer, and of course breast cancer and prostate cancer.”
Drug is value efficient, exec says
Breen stated breast most cancers impacts one in 8 girls, whereas one in 8 males is affected by prostate most cancers.
“We’re targeting the biggest, most prolific cancers with a humane drug, which is a protein, which doesn’t involve cutting, doesn’t involve poisoning, doesn’t involve burning, and which we believe is the way forward that science and healthcare have been crying out for the last 80 years,” he stated.
Associated: Shares & Markets Podcast: Portfolio supervisor navigates the Ok-shaped economic system
“What sets GTE Biopharma apart from others that are trying to do this?” Versace requested.
“From what we’ve seen in our trials, our drug does not have any problems with toxicity,” Breen stated. Our drug is considerably more cost effective as a result of it is a protein and since it is simpler to fabricate. And itdoes not endure from any toxicity points.”
For the reason that remedy is cost-effective, he added, “it’ll be very much better received by health insurers.”
“Are there perhaps opportunities, maybe even greater opportunities, quicker opportunities for GT Biopharma outside the U.S.?” Versace requested.
“Unfortunately, cancer is a worldwide disease that affects everyone,” Breen stated. “It doesn’t matter whether you’re from Australia or Singapore or America or wherever.”
“Therefore, it is very much appropriate that we are looking and exploring, having relationships with other clinical trials centers around the world.”
Amergers and acquisitions legal professional, Breen stated he approaches the enterprise “very much from a perspective of commercialization of what we have.”
“The most important thing is the intellectual property,” he stated. “And I am absolutely on top of it, ensuring that the intellectual property is completely and properly buttoned down and ensuring that we have patents applied for all around the world.”
Breen stated GT Biopharma has “a whole bunch of candidates in our pipeline.”
“We have some very interesting tech,” he stated. “Interesting and better technology. It’s worth bearing that in mind in terms of anyone doing due diligence on our company.”
Associated: Analysts see sturdy luxurious market in 2026
